Abstract

Non-alcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease that can progress to liver fibrosis. Recent clinical advance suggests a reversibility of liver fibrosis, but the cellular and molecular mechanisms underlying NASH resolution remain unclarified. Here, using a murine diet-induced NASH and the subsequent resolution model, we demonstrate direct roles of CD8+ tissue-resident memory CD8+ T (CD8+ Trm) cells in resolving liver fibrosis. Single-cell transcriptome analysis and FACS analysis revealed CD69+CD103CD8+ Trm cell enrichment in NASH resolution livers. The reduction of liver CD8+ Trm cells, maintained by tissue IL-15, significantly delayed fibrosis resolution, while adoptive transfer of these cells protected mice from fibrosis progression. During resolution, CD8+ Trm cells attracted hepatic stellate cells (HSCs) in a CCR5-dependent manner, and predisposed activated HSCs to FasL-Fas-mediated apoptosis. Histological assessment of patients with NASH revealed CD69+CD8+ Trm abundance in fibrotic areas, further supporting their roles in humans. These results highlight the undefined role of liver CD8+ Trm in fibrosis resolution.

The cellular and molecular mechanisms underlying the resolution of non-alcoholic steatohepatitis remain incompletely understood. Here the authors report a single cell-based analysis that identified CD8 + tissue-resident memory T cells, which contribute to resolution of liver fibrosis potentially via elimination of hepatic stellate cells through Fas-mediated cytotoxicity.

Details

Title
CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells
Author
Koda Yuzo 1   VIAFID ORCID Logo  ; Teratani Toshiaki 2 ; Po-Sung, Chu 2 ; Hagihara Yuya 2 ; Mikami Yohei 2   VIAFID ORCID Logo  ; Harada Yosuke 2 ; Tsujikawa Hanako 3 ; Miyamoto Kentaro 2 ; Suzuki, Takahiro 2 ; Taniki Nobuhito 2 ; Sujino Tomohisa 2 ; Sakamoto Michiie 3 ; Kanai Takanori 4   VIAFID ORCID Logo  ; Nakamoto Nobuhiro 2   VIAFID ORCID Logo 

 Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan (GRID:grid.418306.8) (ISNI:0000 0004 1808 2657) 
 Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University School of Medicine, Department of Pathology, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Japan Agency for Medical Research and Development, AMED, Tokyo, Japan (GRID:grid.480536.c) (ISNI:0000 0004 5373 4593) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2554123193
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.